To determine if R
Kock L, Shahab L, Moore G, Beard E, Bauld L, Reid G, et al
Theres a better way: breathe it in
E-Posters - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.02 - SECONDARY PREVENTION P2463 - ESOC25-203 SECONDARY PREVENTION IN STROKE AND TIA PATIENTS UNDER DOACS IN NORTHEREN ISRAEL: A CASE-BY-CASE APPROACH Adi Shemesh 1 , Sivan Bloch 1 1 Carmel medical center, Haifa, Israel Background and Aims: Patients with atrial fibrillation (AF) are at increased risk for CVA & TIA 1 , and those who suffer a breakthrough CVA/TIA while on direct oral anticoagulants (DOACs) are challenging to treat 15
Designed for diabetes, not weight loss The goal of the study was to find out how much weight loss and gastrointestinal side effects happened in adults who were overweight or had obesity and were taking tirzepatide or semaglutide, both of which are approved for type 2 diabetes, in a clinical setting